A quantitative measurement of the human somatic mutation rate

DJ Araten, DW Golde, RH Zhang, HT Thaler… - Cancer research, 2005 - AACR
DJ Araten, DW Golde, RH Zhang, HT Thaler, L Gargiulo, R Notaro, L Luzzatto
Cancer research, 2005AACR
The mutation rate (μ) is a key biological feature of somatic cells that determines risk for
malignant transformation, and it has been exceedingly difficult to measure in human cells.
For this purpose, a potential sentinel is the X-linked PIG-A gene, because its inactivation
causes lack of glycosylphosphatidylinositol-linked membrane proteins. We previously found
that the frequency (f) of PIG-A mutant cells can be measured accurately by flow cytometry,
even when f is very low. Here we measure both f and μ by culturing B-lymphoblastoid cell …
Abstract
The mutation rate (μ) is a key biological feature of somatic cells that determines risk for malignant transformation, and it has been exceedingly difficult to measure in human cells. For this purpose, a potential sentinel is the X-linked PIG-A gene, because its inactivation causes lack of glycosylphosphatidylinositol-linked membrane proteins. We previously found that the frequency (f) of PIG-A mutant cells can be measured accurately by flow cytometry, even when f is very low. Here we measure both f and μ by culturing B-lymphoblastoid cell lines and first eliminating preexisting PIG-A mutants by flow sorting. After expansion in culture, the frequency of new mutants is determined by flow cytometry using antibodies specific for glycosylphosphatidylinositol-linked proteins (e.g., CD48, CD55, and CD59). The mutation rate is then calculated by the formula μ = f/d, where d is the number of cell divisions occurring in culture. The mean μ in cells from normal donors was 10.6 × 10−7 mutations per cell division (range 2.4 to 29.6 × 10−7). The mean μ was elevated >30-fold in cells from patients with Fanconi anemia (P < 0.0001), and μ varied widely in ataxia-telangiectasia with a mean 4-fold elevation (P = 0.002). In contrast, μ was not significantly different from normal in cells from patients with Nijmegen breakage syndrome. Differences in μ could not be attributed to variations in plating efficiency. The mutation rate in man can now be measured routinely in B-lymphoblastoid cell lines, and it is elevated in cancer predisposition syndromes. This system should be useful in evaluating cancer risk and in the design of preventive strategies.
AACR